Kymera Therapeutics’ (KYMR) Outperform Rating Reaffirmed at Oppenheimer

Kymera Therapeutics (NASDAQ:KYMR)‘s stock had its “outperform” rating reaffirmed by equities researchers at Oppenheimer in a research note issued on Wednesday, Benzinga reports. They presently have a $52.00 target price on the stock. Oppenheimer’s price objective indicates a potential upside of 43.41% from the company’s previous close.

Several other analysts have also recently commented on the stock. HC Wainwright restated a “buy” rating and set a $46.00 price objective on shares of Kymera Therapeutics in a research note on Monday, June 17th. B. Riley lifted their price objective on shares of Kymera Therapeutics from $31.00 to $36.00 and gave the company a “neutral” rating in a research note on Tuesday. Seven research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $42.09.

Kymera Therapeutics Stock Performance

KYMR stock traded down $3.18 during trading on Wednesday, reaching $36.26. The company had a trading volume of 417,821 shares, compared to its average volume of 673,502. The firm has a 50-day simple moving average of $33.79 and a 200-day simple moving average of $34.62. The company has a market cap of $2.22 billion, a price-to-earnings ratio of -14.25 and a beta of 2.22. Kymera Therapeutics has a twelve month low of $9.60 and a twelve month high of $45.31.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($0.69) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.04. Kymera Therapeutics had a negative net margin of 194.67% and a negative return on equity of 31.92%. The business had revenue of $10.30 million during the quarter, compared to analysts’ expectations of $14.24 million. During the same period in the previous year, the business posted ($0.70) EPS. The business’s quarterly revenue was up 8.4% compared to the same quarter last year. Sell-side analysts expect that Kymera Therapeutics will post -2.86 earnings per share for the current year.

Insider Activity

In other Kymera Therapeutics news, Director Joanna Horobin sold 8,500 shares of the company’s stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $32.99, for a total value of $280,415.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, Director Joanna Horobin sold 8,500 shares of the stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $32.99, for a total transaction of $280,415.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Bruce Booth sold 16,740 shares of the stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $35.45, for a total transaction of $593,433.00. Following the sale, the director now directly owns 803,792 shares in the company, valued at approximately $28,494,426.40. The disclosure for this sale can be found here. In the last quarter, insiders have sold 479,200 shares of company stock valued at $18,219,660. 15.82% of the stock is currently owned by insiders.

Institutional Trading of Kymera Therapeutics

Large investors have recently made changes to their positions in the company. Quest Partners LLC purchased a new stake in shares of Kymera Therapeutics during the fourth quarter worth approximately $78,000. Comerica Bank increased its stake in Kymera Therapeutics by 13.7% in the first quarter. Comerica Bank now owns 3,324 shares of the company’s stock valued at $134,000 after purchasing an additional 400 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Kymera Therapeutics by 352.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,423 shares of the company’s stock valued at $164,000 after purchasing an additional 5,002 shares during the last quarter. Ameritas Investment Partners Inc. increased its stake in Kymera Therapeutics by 7.8% in the first quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock valued at $164,000 after purchasing an additional 295 shares during the last quarter. Finally, Exchange Traded Concepts LLC increased its stake in Kymera Therapeutics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 7,359 shares of the company’s stock valued at $187,000 after purchasing an additional 1,866 shares during the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.